Your search for

16 results were returned

  1. Legal news
    05 February 2019
    "Effective enforcement of EU competition rules in the pharmaceutical law remains a matter of high priority…"
    www.twobirds.com/en/news/articles/2019/global/effective-enforcement-of-eu-competition-rules-in-pharmaceutical-law

    So notes the Commission's report on competition enforcement in the pharmaceutical sector (2009-2017) published at the end of January 2019.

  2. Legal news
    08 May 2019
    Manufacturing and stockpiling waiver set to limit rights of holders of SPCs for medicines
    www.twobirds.com/en/news/articles/2019/global/manufacturing-and-stockpiling-waiver-set-to-limit-rights-of-holders-of-spcs-for-medicines

    On 17 April 2019, the European Parliament approved, by a large majority, an amendment of the Regulation on Supplementary Protection Certificates ("SPCs").

  3. Legal news
    24 June 2019
    From e-health to digital Health: Telemedicine, Electronic Healthcare File, Artificial Intelligence
    www.twobirds.com/en/news/articles/2019/global/from-e-health-to-digital-health-telemedicine-electronic-healthcare-file-artificial-intelligence

    In the last five decades we have been assisting on the digitalization of society and consequently of the healthcare sector; we have been using terms such as eHealth, medical informatics, health informatics, ...

  4. Legal news
    24 May 2019
    Can CRISPR save the Cavendish?
    www.twobirds.com/en/news/articles/2019/global/can-crispr-save-the-cavendish

    The world's most popular banana is dying. Scientists are using the gene-editing mechanism CRISPR to try and save it from extinction.

  5. Legal news
    22 November 2019
    Access to toxicity study reports and protection of commercial interests
    www.twobirds.com/en/news/articles/2019/uk/access-to-toxicity-study-reports-and-protection-of-commercial-interests

    Gerard Hogan, Advocate General at the Court of Justice of the European Union (“CJEU”) recently delivered an opinion in the pending case between MSD Animal Health Innovation (“MSD”), Intervet international (“Intervet”) ...

  6. Legal news
    07 February 2019
    German Federal Patent Court denies request for preliminary grant of a compulsory license – Where do we go from here?
    www.twobirds.com/en/news/articles/2019/germany/german-federal-patent-court-denies-request-for-preliminary-grant-of-compulsory-license

    Sanofi sought a compulsory licence for the distribution of its high cholesterol drug Praluent® but this was dismissed in preliminary proceedings (docket no: 3 LiQ 1/18).

  7. Legal news
    02 July 2019
    Transfer of value: amendments to the French “anti-gift” provisions by the draft Health Act
    www.twobirds.com/en/news/articles/2019/global/transfer-of-value-amendments-to-the-french-anti-gift-provisions-by-the-draft-health-act

    The French so-called “anti-gift” provisions strictly frame the conditions under which companies in the health sector are allowed to provide advantages, in cash or in kind, to healthcare professionals ("HCPs”)

  8. Legal news
    07 February 2019
    New 2019 French Patent/Software box regime: taxation at a reduced rate of 10%
    www.twobirds.com/en/news/articles/2019/france/new-french-patent-software-box-regime-tax-at-a-reduced-rate-of-7pc

    This new regime, applicable either to types of intangible assets or to a family of products or services, provides taxation at a reduced rate of 10% of net income generated by industrial property including patents and ...

  9. Legal news
    02 December 2019
    The French Health Data Hub becomes reality
    www.twobirds.com/en/news/articles/2019/france/the-french-health-data-hub-becomes-reality

    The French Health Data Hub was born officially with the publication on 30 November 2019 of a ministerial decision (arrêté).

  10. Legal news
    15 November 2018
    Supreme Court defines plausibility in the context of sufficiency
    www.twobirds.com/en/news/articles/2018/uk/supreme-court-defines-plausibility-in-the-context-of-sufficiency

    A majority postulates a new "outward presentation test" to deal with the infringement of second medical use patents.